Form 4: Avenue Therapeutics Director Jay D. Kranzler Sells Shares

Director Jay D. Kranzler of Avenue Therapeutics, Inc. (ATXI) sold 61 shares of common stock at $2.24 per share on November 5, 2024.

Summary

• On November 5, 2024, Jay D. Kranzler, a director of Avenue Therapeutics, Inc. (ATXI), sold 61 shares of the company's common stock.
• The sale was executed at a price of $2.24 per share.
• Following the transaction, Kranzler directly owns 559 shares of Avenue Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a stock sale by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders of a publicly traded company buy or sell the company's securities. These filings provide transparency into the transactions of company directors and officers.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, as it might suggest a lack of confidence in the company's future prospects, although the number of shares sold is small.

Key Dates

Keywords

Form 4, Avenue Therapeutics, ATXI, Director, Jay D. Kranzler, Stock Sale, Beneficial Ownership